(QQXT) NASDAQ-100 Ex-Technology - Overview
Etf: Consumer, Healthcare, Industrial, Telecommunications, Consumer Discretionary
Dividends
| Dividend Yield | 1.22% |
| Yield on Cost 5y | 1.52% |
| Yield CAGR 5y | 40.38% |
| Payout Consistency | 88.5% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 12.2% |
| Relative Tail Risk | 2.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -8.79 |
| Character TTM | |
|---|---|
| Beta | 0.737 |
| Beta Downside | 0.732 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.92% |
| CAGR/Max DD | 0.58 |
Description: QQXT NASDAQ-100 Ex-Technology January 20, 2026
The First Trust NASDAQ-100 Ex-Technology Sector Index Fund (QQXT) is an ETF that must allocate at least 90 % of its net assets-including any investment borrowings-to the securities that make up its benchmark. The benchmark is an equal-weighted version of the NASDAQ-100, stripped of any constituents classified as “technology” under the ICB taxonomy, thereby giving investors exposure to the remaining large-cap non-tech firms.
Key metrics (as of Q4 2025) include an expense ratio of 0.35 % and roughly $2.1 billion in assets under management. The top holdings are typically dominated by health-care (e.g., Pfizer, Amgen), consumer discretionary (e.g., Nike, Starbucks) and industrials, reflecting the index’s sector tilt. Performance is closely tied to macro drivers such as consumer-spending trends, interest-rate cycles, and regulatory developments in health-care, which together account for a large share of the fund’s return variance.
For a deeper, data-driven breakdown of QQXT’s risk-adjusted returns and sector sensitivities, you might find the analytics on ValueRay useful.
What is the price of QQXT shares?
Over the past week, the price has changed by +0.16%, over one month by -0.03%, over three months by +4.01% and over the past year by +3.56%.
Is QQXT a buy, sell or hold?
What are the forecasts/targets for the QQXT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 108.2 | 7.5% |
QQXT Fundamental Data Overview February 09, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 197.0m USD (197.0m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 197.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 197.0m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.63% (E(197.0m)/V(197.0m) * Re(8.63%) + (debt-free company))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)